106 related articles for article (PubMed ID: 34103247)
1. Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer.
Strijker M; van der Sijde F; Suker M; Boermeester MA; Bonsing BA; Bruno MJ; Busch OR; Doukas M; van Eijck CH; Gerritsen A; Groot Koerkamp B; Haj Mohammad N; van Hilst J; de Hingh IH; van Hooft JE; Luyer MD; Quintus Molenaar I; Verheij J; Waasdorp C; Wilmink JW; Besselink MG; van Laarhoven HW; Bijlsma MF;
HPB (Oxford); 2021 Dec; 23(12):1886-1896. PubMed ID: 34103247
[TBL] [Abstract][Full Text] [Related]
2. Impact of disintegrin and metalloproteinase domain-containing protein 12 on pancreatic ductal adenocarcinoma treated with surgical resection and perioperative chemotherapy.
Sakoda T; Uemura K; Kondo N; Sumiyoshi T; Okada K; Seo S; Otsuka H; Murakami Y; Takahashi S
Pancreatology; 2022 May; 22(4):479-487. PubMed ID: 35365420
[TBL] [Abstract][Full Text] [Related]
3. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy.
Veenstra VL; Damhofer H; Waasdorp C; van Rijssen LB; van de Vijver MJ; Dijk F; Wilmink HW; Besselink MG; Busch OR; Chang DK; Bailey PJ; Biankin AV; Kocher HM; Medema JP; Li JS; Jiang R; Pierce DW; van Laarhoven HWM; Bijlsma MF
Oncogenesis; 2018 Nov; 7(11):87. PubMed ID: 30442938
[TBL] [Abstract][Full Text] [Related]
4. Association of Histopathologic Phenotype of Periampullary Adenocarcinomas With Survival.
Williams JL; Chan CK; Toste PA; Elliott IA; Vasquez CR; Sunjaya DB; Swanson EA; Koo J; Hines OJ; Reber HA; Dawson DW; Donahue TR
JAMA Surg; 2017 Jan; 152(1):82-88. PubMed ID: 27732711
[TBL] [Abstract][Full Text] [Related]
5. Role of postoperative adjuvant therapy in resected invasive intraductal papillary mucinous neoplasm of the pancreas: A multicenter external validation.
Choi M; Chong JU; Hwang HK; Seo HI; Yang K; Ryu JH; Roh Y; Kim DH; Lee JH; Lee WJ; Choi SH; Kang CM
J Hepatobiliary Pancreat Sci; 2021 Aug; 28(8):671-679. PubMed ID: 34028187
[TBL] [Abstract][Full Text] [Related]
6. Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study.
Liang L; Ding Y; Yu Y; Liu K; Rao S; Ge Y; Zeng M
BMC Med Imaging; 2021 Apr; 21(1):75. PubMed ID: 33902469
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
8. Major Postoperative Complications Limit Adjuvant Therapy Administration in Patients Undergoing Pancreatoduodenectomy for Distal Cholangiocarcinoma or Pancreatic Ductal Adenocarcinoma.
Macfie R; Berger Y; Liu H; Li T; Imtiaz S; Ang C; Sarpel U; Hiotis S; Labow D; Golas B; Cohen NA
Ann Surg Oncol; 2023 Aug; 30(8):5027-5034. PubMed ID: 37210446
[TBL] [Abstract][Full Text] [Related]
9. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
10. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
11. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
[TBL] [Abstract][Full Text] [Related]
12. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Society based on real-world data.
Tomimaru Y; Eguchi H; Inoue Y; Nagakawa Y; Ohba A; Takami H; Unno M; Yamamoto T; Kawakatsu S; Hayashi T; Higuchi R; Kitagawa H; Hattori S; Fujii T; Hirooka Y; Igarashi H; Kitano M; Kuroki T; Masamune A; Shimizu Y; Tani M; Tanno S; Tsuji Y; Yamaue H; Satoi S; Takeyama Y;
Cancer; 2023 Mar; 129(5):728-739. PubMed ID: 36504020
[TBL] [Abstract][Full Text] [Related]
13. Treatment and overall survival of four types of non-metastatic periampullary cancer: nationwide population-based cohort study.
de Jong EJM; van der Geest LG; Besselink MG; Bouwense SAW; Buijsen J; Dejong CHC; Koerkamp BG; Heij LR; de Hingh IHJT; Hoge C; Kazemier G; van Laarhoven HWM; de Meijer VE; Stommel MWJ; Tjan-Heijnen VCG; Valkenburg-van Iersel LBJ; Wilmink JW; Geurts SME; de Vos-Geelen J;
HPB (Oxford); 2022 Sep; 24(9):1433-1442. PubMed ID: 35135724
[TBL] [Abstract][Full Text] [Related]
14. Identification of an Immune-Related BAT Signature for Predicting Adjuvant Chemotherapy Response and Overall Survival in Patients with Resected Ductal Adenocarcinoma of the Pancreas.
Pu N; Chen Q; Yin H; Zhang J; Zhao G; Habib JR; Chen J; Yu J; Lou W; Wu W
J Gastrointest Surg; 2022 Apr; 26(4):869-886. PubMed ID: 35059985
[TBL] [Abstract][Full Text] [Related]
15. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
16. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Adjuvant Chemotherapy Following Pancreaticoduodenectomy in Elderly Patients With Pancreatic Cancer.
Shin SH; Park Y; Hwang DW; Song KB; Lee JH; Kwon J; Yoo C; Alshammary S; Kim SC
Anticancer Res; 2019 Feb; 39(2):1005-1012. PubMed ID: 30711988
[TBL] [Abstract][Full Text] [Related]
19. The role of coeliac axis resection in resected ductal adenocarcinoma of the distal pancreas: A result of tumour topography or a prognostic factor?
Liu B; Wu J; Li C; Li Y; Qiu H; Lv A; Liu Q; Liu D; Wang Z; Hao C
Pancreatology; 2022 Jan; 22(1):112-122. PubMed ID: 34764022
[TBL] [Abstract][Full Text] [Related]
20. Practice Patterns and Survival in Patients with Resected Pancreatic Ductal Adenocarcinomas (PDAC) - Results from the Multicentre Indian Pancreatic & Periampullary Adenocarcinoma Project (MIPPAP) Study.
Chaudhari V; Ramaswamy A; Srinivas S; Agarwal A; Seshadri RA; Talwar V; Bhargava P; Goel S; Kayal S; Rebala P; Prajapati B; Parikh D; Kothari J; Ch RM; Kadamapuzha JM; Kapoor D; Chaudhary A; Goel V; Singh S; Ghosh J; Lavingia V; Gupta A; Sekar A; Misra S; Vishnoi JR; Soni S; Varshney VK; Bairwa S; Bhandare M; Shrikhande SV; Ostwal V
J Gastrointest Cancer; 2023 Dec; 54(4):1338-1346. PubMed ID: 37273074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
